The following is a summary of the Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript:
Financial Performance:
Nanobiotix reported a Q1 2024 unaudited cash balance of €58.9 million and reassured its cash availability until Q3 2025, including the recently received $20 million milestone.
Business Progress:
Nanobiotix is progressing with NBTXR3, joining forces with Janssen for global commercialization.
They're working on two more platforms, Curadigm and Oocuity, focusing on nanoparticle-based therapies.
Their ongoing collaboration with the MD Anderson Cancer Center plans to have multiple study readouts in the next 12 months.
The company is shifting the sponsorship of the NANORAY-312 trial to Janssen in preparation for potential regulatory submission.
Upon securing more funding, Nanobiotix plans to initiate a new Phase 2 study in a new indication after the NANORAY-312 sponsorship transfer.
They look forward to completing patient recruitment by H1 '26, potential additions to funding and publishes regular updates scheduled for H2 '24.
A crucial update on FDA's approval on the randomized Phase 2 lung cancer trial design is soon to be published. Data on NBTXR3 will also be presented at ASCO.
More details: Nanobiotix IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.